About the Authors
- Ning Li
-
Contributed equally to this work with: Ning Li, Scott Thompson
Affiliation Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
- Scott Thompson
-
Contributed equally to this work with: Ning Li, Scott Thompson
Affiliation The Wistar Institute, Philadelphia, Pennsylvania, United States of America
- David C. Schultz
-
Affiliation The Wistar Institute, Philadelphia, Pennsylvania, United States of America
- Weiliang Zhu
-
Affiliation Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
- Hualiang Jiang
-
Affiliation Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
- Cheng Luo
-
* E-mail: lieberman@wistar.org (PML); cluo@mail.shcnc.ac.cn (CL)
Affiliation Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
- Paul M. Lieberman
-
* E-mail: lieberman@wistar.org (PML); cluo@mail.shcnc.ac.cn (CL)
Affiliation The Wistar Institute, Philadelphia, Pennsylvania, United States of America
Competing Interests
Paul Lieberman has a competing interest as an officer (Founder/Owner and President) in a small biotechnology company called Vironika. A provisional patent has been submitted based on this work. No funding from Vironika was used for this study. The authors confirm that this does not alter their adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: ST CL PML. Performed the experiments: NL ST DCS WZ HJ CL. Analyzed the data: NL ST DCS WZ HJ CL PML. Contributed reagents/materials/analysis tools: DCS HJ CL. Wrote the paper: CL PML.